Lindor, Keith D.

Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: Results of a pilot study

Levy, C., Harnois, D. M., Angulo, P., Jorgensen, R., & Lindor, K. D. (2005) · Liver International

Bone health and osteoporosis researchLiver Diseases and Immunity

Cited by 62

Development of autoimmune hepatitis in primary biliary cirrhosis

Gossard, A. A., & Lindor, K. D. (2007) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 57

Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis

Eaton, J. E., Welle, C. L., Bakhshi, Z., Sheedy, S. P., Idilman, I. S., Gores, G. J., Rosen, C. B., Heimbach, J. K., Taner, T., Harnois, D. M., et al. (2021) · Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 56

Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial

Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D. (2006) · Digestive Diseases and Sciences

Liver Diseases and ImmunityFibromyalgia and Chronic Fatigue Syndrome Research

Cited by 54

Varices in early histological stage primary biliary cirrhosis

Ali, A. H., Sinakos, E., Silveira, M. G., Jorgensen, R. A., Angulo, P., & Lindor, K. D. (2011) · Journal of Clinical Gastroenterology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 50

Effect of Ursodeoxycholic Acid on Serum Lipids of Patients With Primary Biliary Cirrhosis

BALAN, V., DICKSON, E. R., JORGENSEN, R. A., & LINDOR, K. D. (1994) · Mayo Clinic Proceedings

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 48

Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis

Juliusson, G., Imam, M., Björnsson, E. S., Talwalkar, J. A., & Lindor, K. D. (2016) · Scandinavian Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 47

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'

Beuers, U., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., et al. (2015) · Clinics and Research in Hepatology and Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 43

Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)

Tabibian, J. H., & Lindor, K. D. (2014) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 42

Complications, symptoms, quality of life and pregnancy in cholestatic liver disease

Zakharia, K., Tabibian, A., Lindor, K. D., & Tabibian, J. H. (2018) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 42

Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis

Siegel, J. L., Jorgensen, R., Angulo, P., & Lindor, K. D. (2003) · Journal of Clinical Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 40

Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?

Angulo, P., Jorgensen, R. A., & Lindor, K. D. (2001) · The American Journal of Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

The predictors of the presence of varices in patients with primary sclerosing cholangitis

Treeprasertsuk, S., Kowdley, K. V., Luketic, V. A. C., Harrison, M. E., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2010) · Hepatology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 26

P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis

Cheung, A. C., Lammers, W. J., Hirschfield, G. M., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., Pares, A., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 12

964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

Marschall, H.-U., Luketic, V., Lovgren-Sandblom, A., Benthin, L., Kowdley, K., Hirschfield, G., Mason, A., Lindor, K., Gordon, S., Vincent, C., et al. (2012) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 9